OPKO Press Release MIAMI, Aug. 16, 2022 (GLOBE NEWSWIRE) — OPKO Health, Inc. (NASDAQ: OPK), a multinational biopharmaceutical and diagnostics company, today announced that Jon R. Cohen, M.D., is retiring from his role as Executive Chairman and Chief Executive Officer of BioReference Laboratories and Senior Vice President and a Director of OPKO. He will remain as […]
Tag Archives: opko
MIAMI, June 22, 2021 /PRNewswire/ — BioReference Laboratories, Inc., an OPKO Health company (NASDAQ: OPK), today announced a COVID-19 testing program for U.S. based crew and guests who cruise with Royal Caribbean Group, helping provide a safe environment for travelers. Under the agreement, unvaccinated guests will be required to undergo rapid, point-of-care PCR COVID-19 prior to embarking. These guests will […]
360Dx NEW YORK – COVID-19 has driven an uptick in healthcare delivery approaches like telemedicine and point-of-care, home, and direct-to-consumer testing, a shift that some observers believe could continue to accelerate even after the pandemic is over. Click here for full post on 360Dx website
SPOKANE, Wash., March 30, 2021 /PRNewswire/ — Gestalt Diagnostics today announced, that BioReference Laboratories Inc., an OPKO Health company, has selected their digital pathology solution, PathFlow®, to support its pathology business. PathFlow is an enterprise software platform specifically designed to bring the benefits of digital workflow to pathologists and pathology laboratories. Under the agreement, Gestalt is partnering […]
BioReference executes COVID-19 testing program for NBA and NHL for 2020-21 seasons, as well as U.S. Women’s and Men’s National Soccer Teams, Winter X Games and NBA G League ELMWOOD PARK, N.J., January 26, 2021 – BioReference Laboratories, Inc., an OPKO Health company (NASDAQ:OPK), today announced COVID-19 testing agreements for players and officials, as well […]
Nearly 210,000 New York City students, teachers, principals and staff were tested by BioReference with a positivity rate of 0.47% ELMWOOD PARK, N.J., (January 4, 2021) – BioReference Laboratories, Inc., an OPKO Health company (NASDAQ: OPK), today announced the results of COVID-19 molecular PCR tests for public schools throughout New York City’s boroughs, with a positivity rate of […]
The Bills leverage testing capabilities from NFL testing provider, BioReference, to initiate fan testing program ORCHARD PARK, N.Y., December 31, 2020 – Buffalo Bills, 2020 AFC East Division Champions, and BioReference Laboratories, Inc., an OPKO Health company (NASDAQ:OPK), today announced they will be performing fan testing for the AFC Divisional Wild Card playoff game at […]
New offering identifies COVID-19 and Influenza infections with a single sample ELMWOOD PARK, N.J., October 20, 2020 – BioReference Laboratories, Inc., an OPKO Health company (NASDAQ:OPK), is now accepting specimens for a new multiplex COVID-19 and influenza test for use by healthcare providers, clinics and health systems throughout the United States, to aid in the […]
Through New York City, BioReference will be testing students, teachers and staff in nearly 1,000 NYC public schools ELMWOOD PARK, N.J., October 9, 2020 — BioReference Laboratories, Inc., an OPKO Health company (NASDAQ:OPK), today announced the beginning of its COVID-19 testing program for New York City schools throughout the 2020-2021 school year to help ensure a safer school […]
The COVID-19 testing program will test principals, teachers and staff in preparation for a safer back-to-school environment ELMWOOD PARK, N.J., September 2, 2020 — BioReference Laboratories, Inc., an OPKO Health company (NASDAQ:OPK), today began testing New York City principals, teachers and other staff for COVID-19, across the five boroughs, in preparation for a safer back-to-school environment. Through a […]